Neural Connectivity During Therapy for Adolescent PTSD
Neural Connectivity Before and After Each of the Three Treatment Phases of Trauma-focused Therapy for Adolescent Posttraumatic Stress
2 other identifiers
interventional
180
1 country
1
Brief Summary
Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2022
CompletedFirst Posted
Study publicly available on registry
June 21, 2022
CompletedStudy Start
First participant enrolled
November 29, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2027
January 13, 2026
January 1, 2026
4.3 years
June 10, 2022
January 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Mean intensity within functional connectivity map of intrinsic network
functional MRI scans will be used to assess neural connectivity
week 0 (baseline)
Mean intensity within functional connectivity map of intrinsic network
functional MRI scans will be used to assess neural connectivity
week 6
Mean intensity within functional connectivity map of intrinsic network
functional MRI scans will be used to assess neural connectivity
week 12
Mean intensity within functional connectivity map of intrinsic network
functional MRI scans will be used to assess neural connectivity
week 18
Secondary Outcomes (1)
Clinician Administered PTSD Scale - children and adolescents (CAPS-CA)
Baseline to week 18
Study Arms (2)
Trauma-focused cognitive behavioral therapy (TF-CBT)
EXPERIMENTALTrauma-focused Cognitive Behavioral Therapy (TF-CBT) is an evidence-based psychotherapy that is considered the gold-standard treatment for trauma in youth. The TF-CBT model is flexible but it follows a specific order of phases and components, including psychoeducation, emotion regulation skills, processing the trauma narrative, and safety planning. Sessions are provided weekly for 18-weeks.
Treatment As Usual (TAU)
ACTIVE COMPARATORTreatment as usual (TAU) consists of the standard-of-care psychotherapy as provided by licensed clinicians at a local clinic. The order and choice of techniques is based on the knowledge and preferences of the clinicians. Sessions are provided weekly for 18-weeks.
Interventions
Eligibility Criteria
You may qualify if:
- ages 12-17 and Tanner stage 2 or above
- history of interpersonal trauma
- PTSD symptoms with a rating of '2' or higher on at least one symptom from each of the 4 clusters, using the Clinician-Administered PTSD Scale for Children and Adolescents, and having a duration of at least one month
You may not qualify if:
- current or past use of psychiatric medications
- severe suicidal/homicidal ideation
- current hospitalization
- other current psychotherapy or previous treatment with TF-CBT
- history of head injury with loss of consciousness for \>5 minutes
- IQ\<85
- major medical illness
- MRI contraindications (metal in body; braces on teeth)
- psychosis, bipolar 1, autism, developmental disorder, panic disorder
- first-degree family member with diagnosis of psychosis or bipolar I disorder
- substance dependence within the past 3 months or current drug use that is frequent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UT Health Department of Psychiatry
San Antonio, Texas, 78229, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Amy Garrett, PhD
The University of Texas Health Science Center at San Antonio
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- An independent assessor will conduct interviews to quantify symptom severity during and after treatment. The participant will not be given specific information about treatment assignment or the differences between the two treatments.
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 10, 2022
First Posted
June 21, 2022
Study Start
November 29, 2022
Primary Completion (Estimated)
February 28, 2027
Study Completion (Estimated)
February 28, 2027
Last Updated
January 13, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Immediately following publication. No end date.
- Access Criteria
- Researchers who provide a methodologically sound proposal
The data sharing plan and reporting of milestones will conform to all preferred NIMH guidelines, as detailed in the NDA Data sharing terms and conditions. Global unique identifiers (GUIDs) will be generated for each study subject. Data will be submitted to NDA every 6 months. We will provide a data submission agreement. The NDA validation tool will be used frequently. The clinical trial protocol also will be submitted as additional information for every collection. Progress reports will include a statement on the progress of data sharing. 1. Summary of data to be shared: neuroimaging, clinical, demographic, phenotypic, neuropsychological 2. Description of the data dictionaries used to describe the data set: Axis 1 diagnoses, CDI, CAPS-CA, fMRI behavior, beta weights, network correlations 3. Proposed schedule to validate that the data are compliant with the data dictionary: Data will be validated on a quarterly basis